CoChat

Costs, length of stay, and mortality of super‐refractory status epilepticus: A population‐based study from Germany

Strzelczyk, Adam, Ansorge, Sonja, Hapfelmeier, Jana, Bonthapally, Vijayveer, Erder, M. Haim, Rosenow, Felix · 2017 · Epilepsia
Cited by 192

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Abstract

Summary: Objective: Super‐refractory status epilepticus (SRSE) is a severe condition in which a patient in status epilepticus (SE) for ≥24 h does not respond to first‐, second‐, or third‐line therapy. The economic impact of SRSE treatment remains unclear. A health insurance research database was used for a population‐based estimation of SRSE‐associated inpatient costs, length of stay, and mortality in Germany. Methods: An algorithm using International Classification of Diseases, 10th Edition coding and treatment parameters identified and classified patients in a German statutory health insurance database covering admissions from 2008 to 2013 as having refractory SE (RSE) or SRSE. Admissions data in our study refer to these classifications. Associated patient data included costs, procedures, and demographics. Results: The algorithm identified 2,585 (all type) SE admissions, classified as 1,655 nonrefractory SE (64%), 592 (22.9%) RSE, and 338 (13.1%) SRSE, producing database incidence rates of 15.0 in 100,000, 5.2 in 100,000, and 3.0 in 100,000 per year, respectively. Median cost per admission was €4,063 for nonrefractory SE, €4,581 (p < 0.001) for RSE, and €32,706 (p < 0.001) for SRSE. Median length of stay varied significantly between 8 days (mean = 13.6) in nonrefractory SE, 14 days in RSE, and up to 37 days in SRSE. Discharge mortality increased from 9.6% in nonrefractory SE to 15.0% (p < 0.001) in RSE and 39.9% (p < 0.001) in SRSE. Significance: This study evaluated the hospital treatment costs associated with admissions classified by the algorithm as SRSE in Germany. SRSE represented 13% of all SE admissions, but resulted in 56% of all SE‐related costs. The lack of approved treatments and limited number of evidence‐based treatment guidelines highlight the need for further evaluations of the SRSE burden of illness and the potential for further optimization of treatments for SRSE.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/epi.13837

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 192

Metadata

Authors
Strzelczyk, A., Ansorge, S., Hapfelmeier, J., Bonthapally, V., Erder, M. H., & Rosenow, F.
Venue
Epilepsia
Publisher
Wiley
Published
2017-07-06
Volume
58
Issue
9
Pages
1533-1541
ISSN
  • 0013-9580 (ISSN-L)
  • 1528-1167
OpenAlex
W2730221123
Cited by
192
References
2
FWCI
15.54
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Costs, length of stay, and mortality of super‐refractory status epilepticus: A population‐based study from Germany. https://app.cochat.ai/papers/10.1111/epi.13837
The paper
Strzelczyk, A., Ansorge, S., Hapfelmeier, J., Bonthapally, V., Erder, M. H., & Rosenow, F. (2017). Costs, length of stay, and mortality of super‐refractory status epilepticus: A population‐based study from Germany. Epilepsia. https://doi.org/10.1111/epi.13837

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.